This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus
by Zacks Equity Research
Immunovant (IMVT) gains 3% on encouraging fiscal third-quarter 2024 results. Pipeline development is on track, with several data readouts scheduled from both batoclimab and IMVT-1402 programs.
Humacyte (HUMA) Up on HAV BLA Priority Tag for Vascular Trauma
by Zacks Equity Research
Humacyte (HUMA) gains 16% as the FDA accepts its BLA for the HAV bioengineered tissue to treat vascular trauma under Priority Review. A final decision is expected in August 2024.
REGENXBIO's (RGNX) Hunter Syndrome Study Meets Goal, Stock Up
by Zacks Equity Research
REGENXBIO (RGNX) gains 12% on positive top-line results from the phase I/II/III study of its investigational one-time gene therapy candidate, RGX-121, to treat pediatric patients with Hunter syndrome.
Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up
by Zacks Equity Research
Immunome (IMNM) inks an asset purchase agreement with Ayala Pharmaceuticals to acquire the latter's investigational candidate, AL102, being developed for treating desmoid tumors. Stock rises.
Deciphera (DCPH) Q4 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Deciphera (DCPH) reports better-than-expected fourth-quarter 2023 results, wherein both earnings and revenues beat their respective estimates, driven by increased Qinlock sales.
Immunocore Holdings PLC Sponsored ADR (IMCR) Moves 6.9% Higher: Will This Strength Last?
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Best Momentum Stocks to Buy for January 10th
by Zacks Equity Research
IMCR, CPRX and AMPX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 10, 2024.
Should You Buy Immunocore Holdings PLC Sponsored ADR (IMCR) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
New Strong Buy Stocks for January 10th
by Zacks Equity Research
PCRFY, IMCR, CPRX, AMPX and ENS have been added to the Zacks Rank #1 (Strong Buy) List on January 10, 2024.
Immunocore Holdings PLC Sponsored ADR (IMCR) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
How Much Upside is Left in Immunocore Holdings PLC Sponsored ADR (IMCR)? Wall Street Analysts Think 30.32%
by Zacks Equity Research
The consensus price target hints at a 30.3% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Can Immunocore Holdings PLC Sponsored ADR (IMCR) Climb 75.55% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 75.6% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Bears are Losing Control Over Immunocore Holdings PLC Sponsored ADR (IMCR), Here's Why It's a 'Buy' Now
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Wall Street Analysts See a 66.42% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Immunocore Holdings PLC Sponsored ADR (IMCR) points to a 66.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts See a 60.86% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 60.9% in Immunocore Holdings PLC Sponsored ADR (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Why Earnings Season Could Be Great for Immunocore (IMCR)
by Zacks Equity Research
Immunocore (IMCR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Immunocore Holdings PLC Sponsored ADR (IMCR) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Immunocore Holdings PLC Sponsored ADR (IMCR) closed at $48.54, marking a -1.74% move from the previous day.
Immunocore Holdings PLC Sponsored ADR (IMCR) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) closed the most recent trading day at $47.52, moving -0.71% from the previous trading session.
Immunocore Holdings PLC Sponsored ADR (IMCR) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Immunocore Holdings PLC Sponsored ADR (IMCR) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Immunocore Holdings PLC Sponsored ADR (IMCR) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) closed the most recent trading day at $46.71, moving -1.37% from the previous trading session.
Immunocore Holdings PLC Sponsored ADR (IMCR) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) closed the most recent trading day at $53.51, moving +1.61% from the previous trading session.
Immunocore Holdings PLC Sponsored ADR (IMCR) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Immunocore Holdings PLC Sponsored ADR (IMCR). This makes it worthwhile to examine what the stock has in store.
Is a Surprise Coming for Immunocore (IMCR) This Earnings Season?
by Zacks Equity Research
Immunocore (IMCR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Immunocore (IMCR) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Immunocore's (IMCR) Q4 earnings call, investors will likely focus on the sales figure of Kimmtrak - its first-line treatment for metastatic uveal melanoma - and updates on its pipeline candidates.
Investors Heavily Search Immunocore Holdings PLC Sponsored ADR (IMCR): Here is What You Need to Know
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.